Prolixin Related Published Studies
Well-designed clinical trials related to Prolixin (Fluphenazine)
The effects of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity in schizophrenic patients: a double blind study. [2007.03.30]
A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. [2006.04]
Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. [2005.07]
Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. [2005.01]
Well-designed clinical trials possibly related to Prolixin (Fluphenazine)
Long-acting injectable antipsychotics and the development of postinjection
delirium/sedation syndrome (PDSS). [2013]
Mid-term and long-term efficacy and effectiveness of antipsychotic medications
for schizophrenia: a data-driven, personalized clinical approach. [2011]
Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. [2006.09]
Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. [2005.09.01]
Other research related to Prolixin (Fluphenazine)
Fluphenazine decanoate (depot) and enanthate for schizophrenia. [2015]
Fluphenazine (oral) versus placebo for schizophrenia. [2013]
Effectiveness of switching from long-acting injectable fluphenazine or
haloperidol decanoate to long-acting injectable risperidone microspheres: an
open-label, randomized controlled trial. [2012]
Potentiating effect of fluphenazine decanoate and risperidone on development of neuroleptic malignant syndrome. [2011.01]
Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia. [2011]
Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities. [2010.06]
Chronic treatment with fluphenazine alters parameters of oxidative stress in liver and kidney of rats. [2009.07]
Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. [2007.11]
Diphenyl diselenide decreases the prevalence of vacuous chewing movements induced by fluphenazine in rats. [2007.10]
Intracerebroventricular ethanol-induced conditioned place preferences are prevented by fluphenazine infusions into the nucleus accumbens of rats. [2007.04]
Oral fluphenazine versus placebo for schizophrenia. [2007.01.24]
The effects of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity in schizophrenic patients: A double blind study. [2006.11.24]
Adverse extrapyramidal effects in four horse given fluphenazine decanoate. [2006.07.01]
Invited review: fluphenazine augments retinal oxidative stress. [2005.08]
Fluphenazine-induced neuroleptic malignant syndrome in a schizophrenic patient. [2005.06]
Depot fluphenazine decanoate and enanthate for schizophrenia. [2005.01.25]
Other possibly related research studies
Relative risk of glucose elevation during antipsychotic exposure in a Veterans Administration population. [2007.01]
Risks versus benefits of different types of long-acting injectable antipsychotics. [2006]
Series of seizures as a sign of development of recurrent malignant neuroleptic syndrome - a case report. [2006.06]
Antipsychotics produce locomotor impairment in larval zebrafish. [2006.03]
Management of psychosis in Australian general practice. [2006.03]
Importance of oral glucose tolerance test in patient with schizophrenia. [2005.06]
Performance of diadochokinetic movements in schizophrenic patients. [2005.11.15]
Systematic review of antipsychotics for the treatment of hospital-associated delirium in medically or surgically ill patients. [2006.11]
Bait-delivered pimozide causes precocious embryo implantation in mink: a fertility control option for the exotic stoat? [2006]
Pharmacological management of Huntington's disease: an evidence-based review. [2006]
Pharmacotherapy of treatment-resistant combat-related posttraumatic stress disorder with psychotic features. [2006.06]
Penfluridol for schizophrenia. [2006.04.19]
The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment. [2006.11]
Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines. [2006.02]
Phenothiazines induce apoptosis in a B16 mouse melanoma cell line and attenuate in vivo melanoma tumor growth. [2006.01]
[Pharmacokinetic mechanisms underlying resistance in psychopharmacological treatment. The role of P-glycoprotein] [2005.11]
Antipsychotic drugs and QT prolongation. [2005.09]
Possible malignant neuroleptic syndrome that associated with hypothyroidism. [2005.06]
Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders. [2006.03]
All-Cause Treatment Discontinuation in Schizophrenia During Treatment With Olanzapine Relative to Other Antipsychotics: An Integrated Analysis. [2007.06]
Fatal hyponatremia and other metabolic disturbances associated with psychotropic drug polypharmacy. [2007.05]
Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. [2007.04]
Differential effects of typical and atypical antipsychotics on brain myelination in schizophrenia. [2007.07]
Factors related to antipsychotic oversupply among Central Texas Veterans. [2007.06]
Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment. [2007.09.05]
Treatment compliance of outpatients with schizophrenia: patient's attitudes, demographic, clinical and therapeutic variables. [2008.03]
Depression in schizophrenia: comparison of first- and second-generation antipsychotic drugs. [2008.02]
The therapeutic alliance and family psychoeducation in the treatment of schizophrenia: an exploratory prospective change process study. [2008.06]
A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects. [2008.05.08]
Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia. [2008.03]
Typical and atypical antipsychotics--the misleading dichotomy. Results from the Working Group 'Drugs in Psychiatry' (AGATE). [2008]
Two-year rehospitalization rates of patients with newly diagnosed or chronic schizophrenia on atypical or typical antipsychotic drugs: retrospective cohort study. [2008.04]
Does dopamine still have a leading role in advanced Parkinson's disease after subthalamic stimulation? [2008]
Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine. [2008.03]
Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients. [2008.10]
Results of phase 3 of the CATIE schizophrenia trial. [2009.01]
Treatment of a patient with traumatic brain injury-related severe self-injurious behavior. [2009.07]
Use and safety of antipsychotic drugs during pregnancy. [2009.05]
Effects of mental illness and aging in two thalamic nuclei. [2008.12]
The association between class of antipsychotic and rates of hospitalization: results of a retrospective analysis of data from the 2005 Medicare current beneficiary survey. [2009.12]
Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. [2009]
Smoking and schizophrenia. [2009.09]
Pregnancy and atypical antipsychotics. [2009.09]
Effects of omega-3 essential fatty acids (omega-3 EFAs) on motor disorders and memory dysfunction typical neuroleptic-induced: behavioral and biochemical parameter. [2010.04]
In vivo evidence of differential impact of typical and atypical antipsychotics on intracortical myelin in adults with schizophrenia. [2009.09]
Use of aripiprazole in tardive dyskinesia: an open label study of six cases. [2009]
First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients. [2011.12]
Bromperidol decanoate (depot) for schizophrenia. [2011.09.07]
Antipsychotic medication for early episode schizophrenia. [2011.06.15]
The cannabinergic system is implicated in the upregulation of central NGF protein by psychotropic drugs. [2011.05]
Risperidone induced stuttering. [2010.09]
The challenge of patients with severe psychiatric illness who do not access care - a way forward. [2010.10]
[A case of drug-induced syndrome of inappropriate secretion of antidiuretic hormone]. [2010.07]
The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes. [2010.03]
Association between the use of anticholinergic antiparkinson drugs and safety and receptor drug-binding profiles of antipsychotic agents. [2009.12]
Bromperidol decanoate (depot) for schizophrenia. [2012]
Antipsychotic medication for early episode schizophrenia. [2011]
|
